BioXpress Therapeutics SA to Partner the 2011 BIO International Convention

BioXpress Therapeutics to Meet with Companies Interested in Monoclonal Antibody Biosimilars

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
biosimilar bioxpress cancer inflammation

BioXpress Therapeutics SA
BioXpress Therapeutics SA is a privately held biotechnology committed to developing and supplying the highest quality and cost-competitive biosimilar biologic API for unmet need indications such as cancer, inflammation and autoimmunity.

BioXpress Therapeutics currently has 4 biosimilar monoclonal antibody drugs in development with an additional 14 in the pipeline.

Geneva, Switzerland (PRWEB) June 15, 2011

BioXpress Therapeutics SA, a Swiss-based biotechnology company developing high-quality monoclonal antibody (MAb) biosimilars announced today representatives from the Company will be partnering at the 2011 BIO International Convention’s One-on-One Partnering Meetings being held Jun 27-30 in Washington, D.C. at the Walter E. Washington Convention Center.

BioXpress Therapeutics currently has 4 biosimilar monoclonal antibody drugs in development with an additional 14 in the pipeline.

Representatives available to discuss partnering opportunities include: Dr. Cori Gorman and Dr. Curt Scribner. Companies or individuals attending BIO 2011 can schedule meetings with BioXpress Therapeutics by visiting (registration required): oneononepartnering.bio.org/BusinessForum2011/Login.aspx.

BioXpress Therapeutics Partnering Schedule:
Monday, June 27 Business Forum - 12:00 PM - 5:00 PM
Tuesday, June 28 Business Forum - 7:00 AM – 6:00 PM
Wednesday, June 29 Business Forum - 7:00 AM – 6:00 PM
Thursday, June 30 Business Forum - 7:00 AM – 6:00 PM

Each BioXpress Therapeutics biosimilar MAb is developed under strict non-clinical and clinical guidelines as outlined in the European Medicines Agency's "Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies." Furthermore, each BioXpress Therapeutics biosimilar goes through a complete analytical comparison to determine the product is similar to the innovator product.

Having the correct primary sequence is absolutely critical for a biosimilar to have similarity and comparability to the innovator drug. Typically, there are several sequences published for every marketed monoclonal antibody. To ensure BioXpress Therapeutics has identified the correct sequence, the Company has developed a proprietary database of protein sequences based on comprehensive analysis of literature and patent databases. All data entry and data analysis is done by the Company’s team which consists of scientists who have been actively involved in making monoclonal antibody therapeutics since the early 1980s. As a result, the BioXpress scientific team is well-versed in the literature and groups who have developed many of the originator MAbs over the decades. Based on the data from the BioXpress database, the biosimilar protein is expressed and compared to the originator to ensure a valid sequence before moving the drug forward.

About BioXpress Therapeutics
BioXpress Therapeutics SA is a privately held biotechnology committed to developing and supplying the highest quality and cost-competitive biosimilar biologic API for unmet need indications such as cancer, inflammation and autoimmunity. Headquartered in Geneva, Switzerland, BioXpress Therapeutics business is focused on developing unbranded monoclonal antibody (MAb and MAb-like) biosimilar drugs under strict European Medicines Agency (EMA) guidelines.

For more information visit http://www.bioxpress.com.

Media Contact
Robert Meister
602-953-1716
robert(at)meister(dot)net

###


Contact

  • Robert Meister

    (602) 953-1716
    Email

Attachments